Prof. Liu Peng (刘潁) — Multiple Myeloma & Lymphoma | Zhongshan Hospital, Fudan University Shanghai
For international patients with multiple myeloma or lymphoma seeking expert care in Shanghai, Prof. Liu Peng (刘潁) represents one of the most authoritative and clinically accomplished hematologists in China. As the leader of the Department of Hematology at Zhongshan Hospital, Fudan University — ranked No. 1 among Shanghai municipal hospital hematology departments in the city's specialized service capability evaluation — Prof. Liu brings both institutional excellence and personal subspecialty depth to the care of patients with plasma cell disorders and lymphoid malignancies.
Specialty Focus
- Multiple myeloma: newly diagnosed, relapsed, and refractory disease
- Lymphoma: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, mantle cell lymphoma, T-cell lymphomas, Hodgkin lymphoma
- Plasma cell disorders: smoldering myeloma, MGUS, AL amyloidosis
- CAR-T cell therapy for relapsed/refractory myeloma and lymphoma
- Autologous and allogeneic stem cell transplantation
- Novel agent combinations: anti-CD38 antibodies, proteasome inhibitors, IMiDs, BCMA-targeted therapies, BTK inhibitors, anti-CD20 antibodies
Academic & Clinical Titles
- Chief Physician & Professor, Department of Hematology, Zhongshan Hospital, Fudan University
- Vice-Chair, Multiple Myeloma Committee, Chinese Society of Clinical Oncology (CSCO)
- Department ranked No. 1 in hematology service capability among Shanghai municipal hospitals
- Principal investigator in multiple national and international clinical trials in myeloma and lymphoma
Shanghai's Top-Ranked Hematology Department
The Department of Hematology at Zhongshan Hospital has achieved the highest ranking among Shanghai's municipal hospital hematology departments in the city's specialized service capability evaluation — a rigorous assessment of clinical volume, outcomes, technical capability, and research activity. This recognition reflects the department's comprehensive expertise across the full spectrum of hematologic malignancies, from acute leukemia to lymphoma to plasma cell disorders.
For international patients, this institutional ranking matters: it signals that Prof. Liu's department has the infrastructure, multidisciplinary support, and clinical volume to manage complex cases that may have been difficult to treat elsewhere. Zhongshan Hospital's broader ecosystem — including its world-class hepatobiliary, cardiology, and oncology programs — also means that patients with myeloma-related complications (renal failure, cardiac amyloidosis, bone disease) have access to subspecialty expertise across disciplines within a single institution.
Multiple Myeloma: Prof. Liu's Approach
As Vice-Chair of the CSCO Multiple Myeloma Committee, Prof. Liu Peng is one of the national architects of how myeloma is treated in China. His clinical approach integrates international evidence with deep familiarity with the Chinese treatment landscape, including drug availability, reimbursement pathways, and institutional capabilities.
For newly diagnosed patients, Prof. Liu's team conducts comprehensive risk stratification — including cytogenetic analysis (FISH for del17p, t(4;14), t(14;16), gain 1q), M-protein quantification, and organ damage assessment — to guide induction regimen selection and transplant planning. High-risk cytogenetics require more aggressive induction and maintenance strategies, and Prof. Liu's expertise in this area is particularly valuable for patients who have received a standard-risk treatment plan elsewhere.
For relapsed and refractory patients, Prof. Liu's team has access to the full range of novel agents available in China, including daratumumab, carfilzomib, pomalidomide, selinexor, and BCMA-targeted therapies. For triple-class refractory patients, CAR-T cell therapy — an area where China has made globally significant advances — is available through Zhongshan Hospital's program.
Lymphoma: Comprehensive Expertise
Beyond myeloma, Prof. Liu Peng has extensive expertise in the diagnosis and treatment of lymphoma — a diverse group of blood cancers with widely varying biology, treatment approaches, and prognosis. His department manages the full spectrum of lymphoid malignancies:
Aggressive B-cell lymphomas (DLBCL): R-CHOP and its variants remain the backbone of first-line therapy, with polatuzumab vedotin-based regimens and CAR-T therapy for relapsed/refractory disease. Prof. Liu's team has experience with CAR-T therapy for relapsed DLBCL, where China has approved multiple CD19-targeted products.
Indolent lymphomas (follicular, marginal zone): Watch-and-wait strategies, anti-CD20-based chemoimmunotherapy, and novel agents including PI3K inhibitors and BTK inhibitors.
Mantle cell lymphoma: BTK inhibitor-based regimens (ibrutinib, zanubrutinib) have transformed outcomes in this historically difficult-to-treat subtype. China has approved zanubrutinib (a next-generation BTK inhibitor developed by a Chinese company) with extensive clinical experience.
T-cell lymphomas: A heterogeneous group requiring careful histological subtyping and individualized treatment. Prof. Liu's department has experience with CHOP-based regimens, brentuximab vedotin for CD30-positive subtypes, and novel agents in clinical trials.
Hodgkin lymphoma: Highly curable with ABVD or brentuximab vedotin-based regimens, with PD-1 inhibitors for relapsed/refractory disease.
CAR-T Cell Therapy at Zhongshan Hospital
CAR-T cell therapy has transformed outcomes for patients with relapsed/refractory B-cell lymphoma and multiple myeloma. China has been a global leader in CAR-T development, with multiple approved products and one of the world's largest clinical experiences. Zhongshan Hospital's hematology department, under Prof. Liu's leadership, is one of the centers with access to CAR-T therapy for eligible patients.
For international patients considering CAR-T therapy, CMCS can coordinate eligibility assessment, including review of prior treatment history, performance status, organ function, and disease burden — the key factors that determine whether a patient is a suitable candidate.
Who Should Consider Consulting Prof. Liu Peng
- Newly diagnosed myeloma patients seeking expert second opinion on risk stratification and treatment planning
- Relapsed or refractory myeloma patients who have progressed on standard therapies
- Triple-class refractory myeloma patients being evaluated for CAR-T therapy
- Newly diagnosed or relapsed lymphoma patients seeking expert evaluation
- Patients with relapsed/refractory DLBCL being evaluated for CAR-T therapy
- Patients with high-risk cytogenetics or complex myeloma requiring specialized management
- Patients with myeloma-related complications (renal failure, AL amyloidosis, severe bone disease)
- Patients seeking access to clinical trials for novel hematologic therapies
How CMCS Connects You with Prof. Liu Peng
China Medical Concierge Shanghai (CMCS) facilitates access to Prof. Liu Peng for international patients with multiple myeloma, lymphoma, and related hematologic malignancies. Our team manages the full coordination process — from remote case review and medical record translation to appointment scheduling, interpretation, and in-hospital support.
To begin, patients or their families are encouraged to share available medical records including bone marrow biopsy and cytogenetics reports, M-protein quantification (for myeloma), PET-CT or CT imaging, lymph node biopsy pathology (for lymphoma), and prior treatment summaries. Prof. Liu's team can conduct an initial remote assessment before any travel to Shanghai is required.
CMCS provides end-to-end support including:
- Medical record translation (English, Arabic, French, and other languages)
- Remote pre-consultation case review
- Appointment coordination with Prof. Liu Peng's clinic at Zhongshan Hospital
- On-site interpretation during consultations and procedures
- CAR-T therapy eligibility assessment and enrollment coordination
- Post-consultation summary and follow-up support
Contact CMCS to Connect with Prof. Liu Peng
📧 contract@medicalsh.com
💬 WhatsApp: https://wa.me/message/3AM6KAGCW2BAD1
🌐 www.medicalsh.com
CMCS – China Medical Concierge Shanghai connects international patients with Shanghai's leading specialists. We are a health management company, not a hospital. All clinical decisions are made by the treating physician.
0 comments